FDA Issues 55 New Guidances to Speed Up Generic Drugs Development

Generic manufacturers navigating complex ANDA submission strategies now have clearer regulatory footing: the U.S. Food and Drug Administration released a batch of 55 draft product-specific guidances (PSGs) on August 21, 2026, covering bioequivalence methodology, physicochemical characterization, and development pathways for products where no approved generic currently exists.

Of the 55 PSGs, more than 30 address products with no approved ANDAs, including 15 for complex products, a category that historically generates the longest development timelines and the highest rate of ANDA deficiency letters. Eighteen PSGs in this batch are classified as complex, comprising seven new and eleven revised guidances. For regulatory affairs leads, the pipeline prioritization signal is direct: FDA is actively building the evidentiary framework for oncology kinase inhibitors indicated for non-small cell lung cancer, a first-in-class DPP1 inhibitor for non-cystic fibrosis bronchiectasis, and a PARP inhibitor tied to BRCA-mutated cancer indications.

Two GDUFA-funded research outputs embedded in this batch carry particular weight for formulation and analytical teams. The revised PSG for ferumoxytol injection (FERABRIGHT, NDA 219868) introduces updated bioequivalence recommendations alongside additional physicochemical characterization requirements, a combination that will require sponsors to revisit existing comparability protocols before submission. Separately, the new PSG for benzoyl peroxide/tretinoin topical cream (TWYNEO, NDA 214902) offers in vitro bioequivalence studies as an alternative to comparative clinical endpoint studies, a pathway shift that could compress development timelines for sponsors already holding relevant characterization data.

The release advances the objectives of Executive Order 14273, which directs federal agencies to accelerate generic drug approval. FDA has simultaneously updated its Upcoming Product-Specific Guidances web page to signal revisions under active development, giving manufacturers an earlier view into pipeline guidance categories. All 55 PSGs remain in draft status; FDA will accept public comment before finalization, and the agency's stated position is that finalized PSGs reflect current thinking rather than binding requirements.

For QA directors and regulatory leads, the ferumoxytol characterization additions represent the more immediate compliance planning checkpoint, as any sponsor with an active ANDA referencing the prior PSG will need to assess whether existing data packages satisfy the revised physicochemical testing expectations before the guidance is finalized.

Source: U.S. Food and Drug Administration via FDA.gov Drugs RSS Feed, August 21, 2026.